Satisfai Health Inc (“Satisfai”) maintains this website for information, education and communication purposes. You may download material displayed on this website for non-commercial, personal use only, provided you also retain all copyright and other proprietary notices contained on the materials. The contents of the website may not be otherwise copied, distributed or used in any way without Satisfai’s written permission.
This website and any information herein does not and shall not constitute an invitation to invest in Satisfai or its securities or an offer to sell or solicitation of an offer to buy any securities of Satisfai.
Satisfai has taken reasonable steps to include up-to-date and accurate information in this website, but it makes no representations, warranties or assurances as to the accuracy, currency, completeness or reliability of the information provided. Satisfai shall not be liable for any damages or injury resulting from your access to, or inability to access, the website, or from your reliance on any information provided on the website. Without limiting the foregoing, everything on the website is provided to you “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. Specifically, the website provides information about Satisfai. This information was believed to be accurate as of the date it was prepared, however, Satisfai disclaims any duty or obligation to update this information. Information about companies other than Satisfai contained in the website should not be relied upon as being provided or endorsed by Satisfai. Satisfai also assumes no responsibility for, and shall not be liable for any damages resulting from, viruses that may infect your computer equipment or other property on account of your access to, use of, or browsing in the website or your downloading of any materials, data, text, images, video, or audio from the website. Satisfai shall not under any circumstances be liable to any person for any direct, special, incidental, indirect, consequential or other damages resulting from use of or reliance on the information presented, loss of programs, loss of data, loss of use of computer or other systems, loss of profits or revenues or costs of replacement goods even if informed in advance of the possibility of such damages
The use of this website grants no interest, whether proprietary, licensed or otherwise, in the intellectual property rights or any other rights which may exist or are hereafter developed in respect of any portion of the website or its content.
Images of people or places displayed on the website are either the property of, or used with permission by, Satisfai. The use of these images by you, or anyone else authorized by you, is prohibited. Any unauthorized use of the images may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.
Users are advised that when downloaded or displayed on a user’s computer, internet software transmission problems may produce inaccurate or incomplete copies of documents. Satisfai takes no responsibility for the accuracy or completeness of documents or material downloaded or displayed from this website. Use of this website or its content and any reliance on them are at your risk.
Any communication or material you transmit to the website by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like is, and will be treated as, non-confidential and non-proprietary. Anything you transmit or post may be used by Satisfai for any purpose, including but not limited to reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Satisfai will be free to use any ideas, concepts, know-how or techniques contained in any communication that you send to the website for any purpose whatsoever, including, but not limited to, developing, manufacturing and marketing products using such information.
Satisfai may provide links from this website to other websites that may not be administered by Satisfai. Satisfaihas not reviewed all of the sites linked to the website and is not responsible for the contents of any off-site pages or any other sites linked to the website. Your linking to any other off-site pages or other sites is at your own risk.
The sender of any communications to the website or otherwise to Satisfai shall be responsible for the content and information contained therein, including its truthfulness and accuracy.
Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.
Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.
He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.
He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide (www.expertscape.com). He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.
Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.
His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.
He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.
Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.
He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.
He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.
After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.
His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.